Роль асимметричного диметиларгинина у больных ишемической болезнью сердца
Диссертация
Таким образом, в недавних исследованиях было показано, что в развитии атеросклероза важную роль играет эндотелиальная дисфункция, и в первую очередь нарушение выделения оксида азота под действием АДМА. Однако на сегодняшний день данные о многих аспектах ингибирования высвобождения оксида азота под действием АДМА при ИБС и клинической значимости этих нарушений остаются противоречивыми. По этой… Читать ещё >
Список литературы
- Аронов Д.М. Профилактика атеросклероза у лиц с факторами риска и у больных ишемической болезнью сердца / Д. М. Аронов // Русский медицинский журнал. — 2000. — Т. 8, № 8. — С. 351−359.
- Диагностика и лечение стабильной стенокардии. Российские рекомендации. Разработаны Комитетом экспертов ВНОК. — М., 2004. — 28 с.
- Журавлева И.А. Роль окиси азота в кардиологии и гастроентерологии / И. А. Журавлева, И. А. Мелентьев, H.A. Виноградов // Клиническая медицина — 1997. — Т.75,№ 4. —С. 18−21.
- Звенигородская JI.A. Оксид азота как маркер воспаления при стеатогепатите у больных с метаболическим синдромом / J1.A. Звенигородская, Т. В. Нилова // Российский медицинский журнал. — 2008. — Т. 10, № 2. — С.41—47
- Зенков Н.К. NO-синтазы в норме и при патологии различного генеза / Н. К. Зенков, Е. Б. Меньшикова, В. П. Реутов // Вестник РАМН. — 2000. — № 4. — С. 30−34.
- Зотова И.В. Синтез оксида азота и развитие атеросклероза / И. В. Зотова, Д. А. Затейщиков, Б. А. Сидоренко // Кардиология. — 2002. — № 4. — С.58−67.
- Клиническая значимость показателей эндотелиальной дисфункции, оксидативного стресса и гемостаза у больных инфарктом миокарда. / O.JI. Барбараш и др. // Патология кровообращения и кардиохирургия. — 2007. — № 2, —С. 28−33.
- Мазур H.A. Дисфункция эндотелия, монооксид азота и ишемическая болезнь сердца / H.A. Мазур // Терапевтический архив — 2003. — Т. 75, № 3.1. С. 84−86.
- Малышев И.Ю. Введение в биохимию оксида азота. Роль оксида азота в регуляции основных систем организма / И. Ю. Малышев // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 1997. —№ 1.1. С.49−5 5.
- Марков Х.М. Оксид азота. Оксид азота, дисфункция сосудистого эндотелия и патогенез атеросклероза. / Х. М. Марков // Кардиология. — 2009.11, —С. 64−74.
- Марков Х.М. Оксид азота и сердечно-сосудистая система. / Х. М. Марков // Успехи физиологических наук. — 2000. — № 6. — С. 49−65.
- Метельская В.А. Скрининг-метод определения уровня метаболитов оксида азота в сыворотке крови / В. А. Метельская, Н. Г. Туманова // Клиническая лабораторная диагностика. — 2005. — № 6. — С. 15−18.
- Небиеридзе Д.В. Дисфункция эндотелия как фактор риска атеросклероза, клиническое значение ее коррекции / Д. В. Небиеридзе, Р.Г.
- Оганов // Кардиоваскулярная терапия и профилактика. — 2003. — № 3. — С. 86−89.
- Оганов Р.Г. Смертность от сердечно-сосудистых и других хронических неинфекционных заболеваний среди трудоспособного населения России / Р. Г. Оганов, Г. Я. Масленникова // Кардиоваскулярная терапия и профилактика. — 2002. — № 3. — С. 4−9.
- Омельяненко М.Г. Клинико-патогенетическое и диагностическое значение эндотелиальной дисфункции при ишемической болезни сердца у женщин молодого и среднего возраста: диссертация. докт. мед. наук / М. Г. Омельяненко — Иваново, 2004. — 250 стр.
- Омельяненко М.Г. Медикаментозная коррекция эндотелиальной дисфункции при остром коронарном синдроме без подъёма сегмента ST. / М. Г. Омельяненко, Е. Е. Мясоедова // Кардиоваскулярная терапия и профилактика. — 2004. — Том. 3, № 2. — С. 49−53.
- Особенности синтеза оксида азота у больных инфарктом миокарда / О. М. Драпкина и др. // Клиническая медицина. —2000. — № 3. — С. 19−23
- Охотин В.Е. Значение нейрональной, эндотелиальной и индуцибельной изоформ NO-синтаз в гистофизиологии сердечной мышцы / В. Е. Охотин, A.B. Шуклин // Морфология. — 2006. — Т.129. № 1. — С. 7−17.
- Петрищев Н. Н. Физиология и патофизиология эндотелия / Н. Н. Петрищев, Т. Д. Власов // Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция / Н. Н. Петрищев. — СПб.: Издательство СПбГМУ, 2003. — С. 4−38.
- Покровский A.B. Может ли кардиолог спасти больного от инсульта? / A.B. Покровский // Кардиология. — 2003. — № 3. — С. 4−6.
- Реутов В.П. Роль оксида азота в регуляции работы миокарда цикл оксида азота и NO/синтазные системы в миокарде. / В. П. Реутов и др. // Актуальные проблемы транспортной медицины. — 2007. — № 4(10) — С. 89−112.
- Реутов В.П. Биохимическое предопределение NO-синтазной и нитритредуктазной компонент цикла оксида азота / В. Г1. Реутов // Биохимия. — 1999. — Т.64. № 5. — С. 634−651.
- Российские рекомендации, разработанные группой экспертов ВНОК. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. — М., 2007.
- Северина И.С. Растворимая гуанилатциклаза в молекулярном механизме физиологических эффектов оксида азота / И. С. Северина // Биохимия. — 1998. — Вып. 7. — С. 939−947.
- Шальнова С.А. Факторы, влияющие на смертность от ССЗ в российской популяции / С. А. Шальнова, А. Д. Деев, Р. Г. Оганов // Кардиоваскулярная терапия и профилактика. — 2005. — Т. 4, № 1. — С. 4−9.
- Янковская Л.В. Кислородтранспортная функция крови и дисфункция эндотелия у больных со стенокардией и артериальной гипертензией / Л. В. Янковская, В. В. Зинчук, М. А. Лис // Кардиология. — 2007.— № 4. — С. 2227.
- A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease / R.K. Oka et al. // Vasculare Medicine. — 2005. — Vol. 10, № 4. —P. 265−274.
- Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension / J.A. Panza et al. // N. Engl. J. Med. — 1990. — Vol. 323, № 1. — P. 22−27.
- Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells / H. Azuma et al. //Br. J. Pharmacol. — 1995. —Vol. 115. —P. 1001−1004.
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure / P. Vallance et al. // Lancet. — 1992. — Vol. 339. — P. 572−575.
- ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells / M. Chen et al. // Cytokine. — 2008. — Vol. 43, № 2. — P. 149−159.
- ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD (P)H oxidase pathway / Z. Veresh et al. // Hypertension. — 2008. — Vol. 52, № 5. — P. 960−966.
- Adverse effects of cigarette smoke on nitric oxide bioavailability: role of arginine metabolism and oxidative stress / W.Z. Zhang et al. // Hypertension. — 2006. — Vol. 48. — P. 278−285.
- Aging and endothelial function in normotensive subjects and patients with essential hypertension / S. Taddei et al. // Circulation. — 1995. -— Vol. 91, № 7.1. P. 1981−1987.
- An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes / R.H. Boger et al. // J. Am. Coll. Cardiol. — 2000.1. Vol. 36. — P. 2287−2295.
- Angina, myocardial ischemia and coronary disease: gold standards, operational definitions and correlations. / M.A. Hlatky et al. // Journal of Clinical Epidemiology. — 1989. — Vol. 42. — P. 381−384.
- Angiotensin converting enzyme inhibition and angiotensin II ATI-receptor blockade reduce the levels of asymmetrical N (G), N (G) -dimethylarginine in human essential hypertension / C. Delles et al. // Am. J. Hypertens. — 2002. — Vol. 15, —P. 590−593.
- Angiotensin-Converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus / A. Ito et al. // Circulation Journal. — 2002. — Vol. 66. — P. 811−815.
- Angiotensin-Converting enzyme gene polymorphism is associated with endothelium-dependent vasodilation in never treated hypertensive patients / F. Perticone et al. // Hypertension. — 1998. — Vol. 31, № 4. — P. 900−905.
- Aspirin reduces endothelial cell senescence / S.M. Bode-Boger et al. // Biochem. Biophys. Res. Commun. — 2005. — Vol. 334. — P. 1226−1232.
- Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats / S. Deng et al. // Acta Pharmacol. Sin. — 2004. — Vol. 25. — P. 1633−1639.
- Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: Effect of combination with oral L-arginine / G.I. Boger et al. // J. Am. Coll. Cardiol. — 2007. — Vol. 49, № 23. —P. 2274−2282.
- Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia / R.H. Boger et al. // Circulation. — 1998. —Vol. 98. —P. 1842−1847.
- Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans / J.R. Chan et al. // Arterioscler. Thromb. Vase. Biol. — 2000. — Vol. 20. — P. 1040−1046.
- Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure / C. Duckelmann et al. // Arterioscler. Thromb. Vase. Biol. — 2007. — Vol. 27, № 9. — P. 2037−2042.
- Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study / C. Iribarren et al. // Eur. J. Cardiovasc. Prev. Rehabil. — 2007. — Vol. 14. — P. 222−229.
- Asymmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. / D.J. Jiang et al. // Atherosclerosis. — 2009. — 205(2). — P. 554−560.
- Asymmetric dimethylarginine and coronary collateral vessel development. / S.A. Kocaman et al. // Coron. Artery Dis. — 2008. — Vol. 19, № 7. — P. 469 474.
- Asymmetric dimethylarginine and hyperhomocysteinemia in patients with acute myocardial infarction / C. Korandji et al. // Clin. Biochem. — 2007. — Vol. 40, № 1−2. — P. 66−72.
- Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes diabetes care / K. Krzyzanowska et al. // Diabetes Care. — 2007. — Vol. 30, № 7. — P. 1834−1839.
- Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes / K. Krzyzanowska et al. // Atherosclerosis. — 2006. — Vol. 189, № 1. — P. 236−240.
- Asymmetric dimethylarginine and reduced nitric oxide bioavailability young black in african men / N. Melikian et al. // Hypertension. — 2007. — Vol. 49. —P. 873−877.
- Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease / F. Mittermayer et al. // Arterioscler. Tromb. Vase. Biol. — 2006. — Vol. 26, № 11. — P. 2536−2540.
- Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study / R. Schnabel et al. // Circulation Research. — 2005. — Vol. 97, № 5. — P. E53-E59.
- Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation / I.V. Smirnova et al. // Am. J. Physiol. Heart Circ. Physiol. — 2004. — Vol. 287. — P. H782-H789.
- Asymmetric dimethylarginine (ADMA) is a critical regulator of myocardial reperfusion injury. / M.C. Stiihlingera et al. // Cardiovascular Research. — 2007. — Vol. 75, № 2. — P. 417−425.
- Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease / C. Zoccali et al. // J. Am. Soc, Nephrol. — 2002. — Vol. 13, № 2. — P. 490−496.
- Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease / T.M. Lu et al. // Clin. Cardiology. — 2003. — Vol. 26. — P. 458−464.
- Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension / H. Matsuoka et al. // Hypertension. — 1997. — Vol. 29. — P. 242−247.
- Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? / V.P. Valkonen et al. // Atheroscler. Suppl. — 2003. — Vol. 4. — P. 19−22.
- Behowski J., Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy / J. Beltowski, A. Kedra // Pharmacol. Rep. — 2006. — 58(2). —P. 159−178.
- Beneficial effects of probucol on endothelial function in patients with acute coronary syndrome / H.M. Dong et al. // Zhonghua Xin Xue Guan Bing Za Zhi. — 2006. — Vol. 34, № 7. — P. 609−612.
- Biotransformation of nitric oxide, nitrite and nitrate / K. Yoshida et al. // Int. Arch. Occup. Environ. Health. — 1983. — Vol. 52. — P. 103−115.
- Bode-Boger SM, Scalera F, Martens-Lobenhoffer J. Asymmetric dimethylarginine (ADMA) accelerates cell senescence / S.M. Bode-Boger, F Scalera, J. Martens-Lobenhoffer // Vase. Med. — 2005. — Vol. 10, Suppl. 1. — P. S65-S71.
- Boger R.H., Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease / R.H. Boger, C. Zoccali // Atherosclerosis Supplements. — 2003. — Vol. 4. — P. 23−28.
- Bryan N.S., Grisham M.B. Methods to detect nitric oxide and its metabolites in biological samples / N.S. Bryan, M.B. Grisham // Free Radie. Biol. Med. — 2007. — Vol. 43, № 5. — P. 645−657.
- Campeau L. Grading of angina pectoris / L. Campeau // Circulation. — 1976. — 54(3) — P. 522−523.
- Changes of asymmetric dimethylarginine, nitric oxide, tetrahydrobiopterin, and oxidative stress in patients with acute myocardial infarction by medical treatments / T. Yada et al. // Clin. Hemorheol. Microcirc. — 2007. — Vol. 37, № 3. —P. 269−276.
- Chest pain on questionnaire and prediction of major ischaemic heart disease events in men. / F.C. Lampe et al. // European Heart Journal. — 1998. — Vol. 19. —P. 63−73.
- Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits / A.J. Cayatte et al. // Arterioscler. Thromb. — 1994. — Vol. 14. —P. 753−759.
- Cooke J.P. Does ADMA cause endothelial dysfunction? / J.P. Cooke // Arterioscler. Tromb. Vase. Biol. — 2000. — Vol. 20, № 9. — P. 2032−2037.
- Cooke J .P. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis / J.P. Cooke // European Journal of Clinical Pharmacology. — 2006. — Vol. 62, Suppl. 1. — P. 115- 121.
- Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis / R. Elesber et al. // Eur. Heart J. — 2006. — Vol. 27, № 7. — P. 824−831.
- Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death / S.M. Hollenberg et al. // Circulation. — 2001. — Vol. 104, № 25. — P. 3091−3096.
- Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events / P.V.Targonski et al. //Circulation. — 2003. — Vol. 107, № 22. —P. 2805−2809.
- Cylwik D. L-arginine and cardiovascular system / D. Cylwik, A Mogielnicki, W. Buczko // Pharmacological Reports. — 2005. — Vol. 57, № 1. — P. 14−22.
- Determination of nitric oxide using fluorescence spectroscopy / A.M. Miles et al. // Methods Enzymol. — 1996. — Vol. 268. — P. 105−120.
- Determination of asymmetric dimethylarginine (ADMA) by a novel ELISA assay. / F. Schulze et al. // Clin. Chem. Lab. Med. — 2004. — 42(12). — P. 1377−1383.
- Determination of a reference value for N, N-dimethyl-L-arginine in 500 subjects / F. Schulze et al. // Eur. J. Clin. Invest. — 2005. — Vol. 35. — P. 622 626.
- Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry / K. Vishwanathan et al. // J. Chromatogr. B. Biomed. Sei. Appl. — 2000. — Vol. 748, № 1. — P. 157−166.
- Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis / H. Dayoub et al. // Circulation. — 2003. — Vol. 108. — P. 3042−3047.
- Dimethylarginine dimethylaminohydrolase (DDAH): Expression, regulation and function in the cardiovascular and renal systems / F. Palm et al. // Am. J. Physiol. Heart Circ. Physiol. — 2007. — Vol. 293, № 6. — P. 3227−3245.
- Effect of local intraarterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers / A. Calver et al. // J. Hum. Hypertens. — 1993. — Vol. 7. — P. 193−194.
- Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia / T.M. Lu et al. // Am. J. Cardiol. — 2004. — Vol. 94. —P. 157−161.
- Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. / A. Oguz et al. // Anadolu. Kardiyol. Derg. — 2007. — Vol. 7, № 4. — P. 383−387.
- Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells / T. Osanai et al. // Hypertension. — 2003. — Vol. 42. — P. 985−990.
- Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. / H.J. Paiva et al. // Cardiovasc. Pharmacol. —- 2003. — Vol. 41. — P. 219−222.
- Effects of asymmetric dimethylarginine (ADMA) infusion in humans / J. T Kielstein et al. // Eur. J. Clin. Pharmacol. — 2006. — Vol. 62, Suppl. 13. — P. 39−44.
- Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits / S.M. Bode-Boger et al. // Biochem. Biophys. Res. Commun. — 1996. — Vol. 219. —P. 598−603.
- Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery / R. Maas et al. // Crit. Care Med. — 2007. — Vol. 35, № 8, —P. 1876−1881.
- Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events / T.K. Krempl et al. // Eur. Heart. J.2005. — Vol. 26, № 18. —P. 1846−1851.
- Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study. / J.A. Chirinos et al. // Hypertension. — 2008. — Vol. 52, № 6. — P. 1051−1059.
- Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis / H. Miyazaki et al. // Circulation. — 1999. — Vol. 99. — P. 1141−1146.
- Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. / F. Perticone et al. // Int. J. Cardiol. — 2009 Jan 23. [Epub ahead of print].
- Endothelial dysfunction induced by hyperhomocyst (e)inemia: role of asymmetric dimethylarginine / M.C. Stuhlinger et al. // Circulation. — 2003. — Vol. 108.—P. 933−938.
- Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress / M. Valgimigli et al. // Arch. Biochem. Biophys. — 2003. — Vol. 420. — P. 255−261.
- Furchgott R.F. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine / R.F. Furchgott // Nature. — 1980. — Vol. 288. —P. 373−376.
- Grisham M.B. Quantitation of nitrate and nitrite in extracellular fluids / M.B. Grisham, G.G. Johnson, J.R. Jr. Lancaster // Methods Enzymol. — 1996. — Vol. 268. — P. 237−246.
- Heart Disease and Stroke Statistics-2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee / T. Thorn et al. // Circulation. —- 2006. — Vol. 113, № 6. — P. e85-el51.
- Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine / M.C. Stuhlinger et al. // Circulation. — 2001. — Vol. 104.—P. 2569−2575.
- Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. / M. Zeller et al. // Arteriosclerosis, Thrombosis, and Vascular Biology. — 2008. — Vol. 28. — P. 954- 960.
- Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans / M.A. Creager et al. // J. Clin. Invest. — 1990. — Vol. 86, № 1. —P. 228−234.
- Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus / M.T. Johnstone et al. // Circulation. — 1993. — Vol. 88, № 6. — P. 2510−2516.
- Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase / K.Y. Lin et al. // Circulation. — 2002. — Vol. 106. — P. 987−992.
- Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects / M.P. Schlaich et al. // Circulation. — 2004. — Vol. 110, № 24. — P. 3680−3686.
- Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects / M.P. Schlaich et al. // Circulation. — 2004. — Vol. 110, № 24. — P. 3680−3686.
- Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure / M. Usui et al. // Life Sci. — 1998. — Vol. 62. — P. 2425−2430.
- Increased protein arginine methylation in chronic hypoxia: role of protein arginine methyltransferases / A.O. Yildirim et al. // Am. J. Respir. Cell. Mol. Biol. — 2006. — Vol. 35, № 4. — P. 436−443.
- Involvment of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction / D.J. Jiang et al. // Biochem. Biophys. Res. Commun. — 2006. — Vol. 349, № 2. — P. 683−693.
- Kalinowski L., Malinski T. Endothelial NADH/NADPH dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction / L. Kalinowski, T. Malinski // Acta. Biochim. Pol. — 2004. — Vol. 51. —P. 459−469.
- Keim M. Nitric oxide metabolism and breakdown / M. Keim // Biochimica et Biophysica Acta. — 1999. — Vol. 1411. — P. 273−289.
- Keim M. Metabolic fate of nitric oxide and related N-oxides / M. Keim, K. Yoshida // Methods in nitric oxide research // M. Feelisch, J.S. Stamler. — John Wiley and Sons, Chichester, 1996. — P. 47−58.
- L-Arginine protects from ischemia-reperfusion-induced endothelial dysfunction in humans in vivo / J. Pernovv et al. // J. Appl. Physiol. — 2003. — Vol. 95, № 6. — P. 2218−2222.
- L-arginine administration reduces neointiinal formation after stent injury in rats by a nitric oxide-mediated mechanism / P. Vcermeersch et al. // Arterioscler. Tromb. Vase. Biol. — 2001. — Vol. 21. — P. 1604−1609.
- L-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease / Wei-Hsian Yin et al. // J. Am. Coll. Cardiol. — 2002. — Vol. 39. — P. 37−45.
- LDL cholesterol upregulates synthesis of ADMA in human endothelial cells: involvment of S-adenosylmethionine-dependent methyl transferases / R.H. Boger et al. // Cire. Res. — 2000. — Vol. 87, № 2. — P. 99−105.
- Leiper J., Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases / J. Leiper, P. Vallance // Cardiovasc Res. — 1999. — Vol. 43, № 3. — P. 542−548.
- Li H. Nitric oxide in the pathogenesis of vascular disease / H. Li, U. Forstermann // J. Pathol. — 2000. — Vol. 90. — P. 244−254.
- Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction / J.A. Suwaidi et al. // Circulation. — 2000. — Vol. 101, № 9. — P. 948−954.
- Lu C.W., Xiong Y, He P. Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein / C. W. Lu, Y. Xiong, P. He // Nitric Oxide. — 2007.1. Vol. 16, № 1.—P. 94−103.
- Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity / U. Garbin et al. // Pharmacol. Res. — 2007. — Vol. 56, № 6. — P. 515−521.
- Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. / A.F. Pasini et al. //Ain. J. Hypertens. — 2008. — Vol. 21, № 11. — P. 1251−1257.
- Nitric oxyde syntase gene therapy reduced adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. / Q. HuSheng et al. // Circulation. — 1999. — Vol. 99. — P. 2979−2982.
- Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance / A. Surdacki et al. // Metabolism. — 2007. — Vol. 56, № 1. — P. 77−86.
- Ogawa T. Occurrence of a new enzyme catalyzing the direct conversion of NG, NG-dimethyl-L-arginine to L-citrulline in rats / T. Ogawa, M. Kimoto, K. Sasaoka. // Biochem Biophys Res Commun. — 1987. — Vol. 148. — P. 671−677.
- Oguz A, Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome / A. Oguz, M. Uzunlulu // Int. Heart J. — 2008. — 49, № 3. — P. 303−311.
- Oral L-arginine improves hemodynamic responses to stress and reduces plasma homocysteine in hypercholesterolemic men / S.G. West et al. // The Journal of Nutrition. — 2005. — Vol. 135, № 2. — P. 212−217.
- Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. / H. Dayoub et al. // Stroke. — 2008. — Vol. 39, № 1. — P. 180 184.
- Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. / J. Jacobi etal. //Circulation. — 2005. — Vol. 111, № 11. — P. 1431−1438.
- Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients / H. Kocak et al. // Am. J. Nephrol. — 2008. — Vol. 28, № 1. — P. 91−96.
- Paik W.K., Kim S. Protein methylase I. Purification and properties of the enzyme / W.K. Paik, S. Kim // J. Biol. Chem. — 1968. — Vol. 243. — P. 21 082 114.
- Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment / S. Bae et al. // Am. J. Cardiol. — 2005. — Vol. 15. — P. 729−733.
- Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. / R.H. Boger et al. // Circulation. -— 2009. — Vol. 119, № 12. —P. 1592−1600.
- Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study / K. Furuki et al. // Atherosclerosis. — 2007. — Vol. 191, № 1. — P. 206−210.
- Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. / K. Furuki et al. // Hypertension Res. — 2008. — Vol. 31, № 6. — P. 1185−1189.
- Plasma level of ADMA and adverse cardiovascular events after percutaneous coronary intervention / T. Lu et al. // Eur. Heart J. — 2003. — Vol. 24. —P. 1912−1919.
- Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy / H. Paiva et al. // Metabolism. -— 2003. — Vol. 52. —- P. 303−307.
- Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study / C. Zoccali et al. // Lancet. —2001. —Vol. 358. —P. 2113−2117.
- Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS) / J.A. Simon et al. // Circulation. — 2001. — Vol. 103, № 5. — P. 638−642.
- Prognostic value of coronary vascular endothelial dysfunction / J.P. Halcox et al. // Circulation. — 2002. — Vol. 106, № 6. — P. 653−658.
- Prognostic significance of endothelial dysfunction in hypertensive patients / F. Perticone et al. // Circulation. — 2001. — Vol. 104, № 2. — P. 191 196.
- Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension / A. Surdacki et al. // J. Cardiovasc. Pharmacol. — 1999. — Vol. 33. — P. 652 658.
- Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats / D. Li et al. // Can. J. Physiol. Pharmacol. — 2007. — Vol. 85, № 8. — P. 783 -789.
- Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase / R.J. MacAllister et al. // Br. J. Pharmacol. — 1996. — Vol. 119. —P. 1533−1540.
- Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease / J. Wang et al. // Atherosclerosis. — 2008. — Vol. 197, № 2. — P. 853−859.
- Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography / E. Cavusoglu et al. // Coron. Artery Dis. — 2009. — Vol. 20, № 2.1. P. 112−117.
- Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine / H.M. Eid et al. // Metabolism.2004. —Vol. 53. —P. 1574−1579.
- Relationship between plasma asymmetrical dimethylarginine and coronary artery disease / Y. Song et al. // Zhonghua Yi Xue Za Zhi. — 2007. — Vol. 87, № 22. —P. 1527−1530.
- Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension / A. Ito et al. // Jpn. Cire. J. — 2001. — Vol. 65. — P. 775−778.
- Risk of acute coronary events and serum concentration of ADMA / V.P. Valkonen et al. // Lancet. — 2001. — Vol. 358. — P. 2127−2128.
- Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II / M.F. Chen et al. // J. Vase. Res. — 2007. — Vol. 44, № 5. — P. 391−402.
- Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling / T. Le Tourneau et al. // J. Am. Coll. Cardiol. — 1999. — Vol. 33. — P. 876−882.
- Ross R. Atherosclerosis — an inflammatory disease / R. Ross // The New England journal of medicine. — 1999. — Vol. 340, № 2. — P. 115−126.
- Saifutdinov R.G. Electron paramagnetic resonance in biochemistry and medicine / R.G. Saifutdinov, L.I. Larina, T.I. Vakulskaya, M.G. Voronkov. — New York, 2000. — P. 268.
- Salt loading on plasma asymmetrical dimethylarginine and the protective role of potassium supplement in normotensive salt-sensitive asians / Y. Fang et al. // Hypertension. — 2006. — Vol. 48, № 4. — P. 724−729.
- Schachinger V. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease / V. Schachinger, M.B. Britten, A.M. Zeiher // Circulation. — 2000. — Vol. 101, № 16. — P. 1899−1906.
- Schwedhelm E. Quantification of ADMA: analytical approaches / E. Schwedhelm 11 Vase. Med. — 2005. — Vol. 10, Suppl. 1. — P. S89-S95.
- Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland / P. Jousilahti et al. // Circulation. — 1999. — Vol. 99, № 9. — P. 1165−1172.
- Simon T. Hormone replacement therapy in postmenopausal women at cardiovascular risk: epidemiology and clinical trials / T. Simon, P. Jailon // Eur. Heart J. Suppl. — 2000. — P. 2−6.
- Sowers J.R. Hypertension, angiotensin II, and oxidative stress / J.R. Sowers // The New England journal of medicine. — 2002. — Vol. 346, № 25. — P.1999−2001.
- Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake / N. Fujiwara et al. // Circulation. — 2000. — Vol. 101. — P. 856−861.
- Subpressor dose of asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition / J.T. Kielstein et al. // Kidney Blood Press. Res. — 2004. — Vol. 27. — P. 143−147.
- Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. / T. Thum et al. // J. Am. Coll. Cardiol. — 2005. — Vol. 46, № 9. —P. 1693−1701.
- Sydow K., Munzel T. ADMA and oxidative stress / K. Sydow, T. Munzel // Atheroscler. Suppl. — 2003. — Vol. 4. — P. 41−51.
- Tannenbaum S.R. Nitrate and nitrite: origin in humans / S.R. Tannenbaum // Science. — 1994. — Vol. 205. — P. 1333−1335.
- Teerlink T. ADMA metabolism and clearance / T. Teerlink // Vasculare Medicine. — 2005. -—- Vol. 10, Suppl. 1, —P. 73−81.
- Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function / Y. Ono et al. // Int. Heart J. — 2009. — Vol. 50, № 1. — P. 73−83.
- Tesfamariam B. The effects of HMG-CoA reductase inhibitors on endothelial function / B. Tesfamariam // Am. J. Cardiovasc. Drugs. — 2006. — Vol. 6, —P 115−120.
- The effects of G-CSF-induced mobilization of progenitor cells are limited by ADMA. / A. Goette et al. // Int. J. Cardiol. — 2009.
- The cardiovascular risk marker ADMA is not affected by venous thromboembolism / D.G. Haider et al. / Translational Research. — 2006 — Vol. 148. —P. 26−29.
- The association of Rose questionnaire angina pectoris and coronary calcification in a general population: The Rotterdam Coronary Calcification Study. / H.H. Oei et al. // Annals of Epidemiology. — 2004. — Vol. 14, № 6. — P. 431 436.
- The L-arginine:nitric oxide pathway is the major source of plasma nitrite in fasted humans / P. Rhodes et al. // Biochem. Biophys. Res. Commun. — 1995.1. Vol. 209. — P. 590−596.
- The effect of plasma asymmetric dimethylarginine (ADMA) level and L-arginine/ADMA ratio on the development of coronary collaterals. / M.T. Se^uk et al. // Turk. Kardiyol. Dern. Ars. — 2008. — Vol. 36, № 3. p. 150−155.
- Vallance P. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway / P. Vallance, J. Leiper. // Arterioscler. Thromb. Vase. Biol. — 2004. — Vol. 24. — P. 1023−1030.
- Vallance P. Asymmetric dimethylarginine and kidney disease — marker or mediator? P. Vallance, J. Leiper. // J. Am. Soc. Nephrol. — 2005. — Vol. 16.1. P. 2254−2256.
- Vanhoutte P.M. Arginine and arginase: endothelial NO synthase double crossed? // Vanhoutte P.M. / Cira Res. — 2008. — Vol. 102. — P. 866−868.
- Vanhoutte P.M. Endothelial dysfunction and vascular disease // P.M. Vanhoutte, H. Shimokawa, E.H. Tang / Acta Physiol (Oxf). — 2009. — Vol. 196(2). —P. 193−222.
- Vanhoutte P.M. Endothelial dysfunction: the first step toward coronary arteriosclerosis. / P.M. Vanhoutte // Circ. J. — 2009. — Vol. 73, № 4. — P. 595 601.
- Vanhoutte P.M. Endothelial dysfunction and atherosclerosis / P.M. Vanhoutte // Eur. Heart J. — 1997. — Vol. 18, Suppl. E. — P. 19−29.
- Vanhoutte P.M. Endothelium-dependent contractions: when a good guy turns bad! // P.M. Vanhoutte, E.H. Tang / J. Physiol. — 2008. — Vol. 586. — P. 5295−5304.
- Vanhoutte P.M. How we learned to say NO // P.M. Vanhoutte / Arterioscler. Thrombi Vasc^ Biol. — 2009. — Vol. 29(8). — P. 1156−1160.
- Vasoreactivity of the culprit lesion in unstable angina / P. Bogaty et al. // Circulation. — 1994. — Vol. 90, № 1. — P. 5−11.
- Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women / K. Krzyzanowska et al. // The Journal of Clinical Endocrinology & Metabolism. — Vol. 89, № 12. — P. 6277−6281.
- Yazici M. Association between nitric oxide levels on myocardial injury in non-ST elevation acute coronary syndromes / M. Yazici, S. Demircan, K. Durna // J. Thromb. Thrombolysis. — 2007. — Vol. 24, № 2. — P. 145−151.
- Yokoyama M. Oxidant stress and atherosclerosis / M. Yokoyama // Curr. Opin. Pharmacol. — 2004 — Vol. 4. — P. 110−115.
- Zeiher A.M. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function / A.M. Zeiher, V. Schachinger, J. Minners // Circulation. — 1995. — Vol. 92, № 5. — P. 1094−1100.
- Zhang W.R., Chen B.M., Xiong Y. Changes of serum asymmetric dimethylarginine in essential hypertension before and after the treatment / W.R. Zhang, B.M. Chen, Y. Xiong // Zhong Nan Da Xue Xue Bao Yi Xue Ban. — 2005. — Vol. 30, № 1. — P. 57−59.